CRBU — Caribou Biosciences, Inc.
$0.36
$-0.02 (-4.81%)
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
Market Cap
$39.10M
Forward P/E
-0.4x
52-Week Range
N/A
CRBU Price History
Revenue vs. Net Income
$11.2M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$112M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-90.8%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.3x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
12.2%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+3.4%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
